Hepion Pharmaceuticals Inc (HEPA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) has a cash flow conversion efficiency ratio of -0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-332.77K) by net assets ($2.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HEPA equity to assets ratio to measure how much of total assets are equity-financed.
Hepion Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Hepion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hepion Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Hepion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hepion Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Modiin Energy-Limited Partnership
TA:MDIN-L
|
0.177x |
|
NamR SA
PA:ALNMR
|
-0.280x |
|
Eason Technology Limited
NYSE MKT:DXF
|
0.000x |
|
ULTRA LITHIUM
F:QFB
|
-0.007x |
|
Silver Spruce Resources Inc
V:SSE
|
0.000x |
|
LIQUID AVATAR TECHNO.INC.
F:4T5
|
N/A |
|
Trifast plc
LSE:TRI
|
0.049x |
|
Hydro Exploitations SA
PA:MLHYE
|
N/A |
Annual Cash Flow Conversion Efficiency for Hepion Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Hepion Pharmaceuticals Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see HEPA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.67 Million | $-3.27 Million | -1.226x | -112.54% |
| 2024-12-31 | $-1.86 Million | $-18.22 Million | 9.776x | +274.08% |
| 2023-12-31 | $7.28 Million | $-40.89 Million | -5.616x | -700.86% |
| 2022-12-31 | $49.86 Million | $-34.96 Million | -0.701x | -108.85% |
| 2021-12-31 | $93.00 Million | $-31.22 Million | -0.336x | +15.84% |
| 2020-12-31 | $40.52 Million | $-16.17 Million | -0.399x | +17.65% |
| 2019-12-31 | $15.62 Million | $-7.57 Million | -0.484x | +93.88% |
| 2018-12-31 | $1.98 Million | $-15.65 Million | -7.922x | -257.35% |
| 2017-12-31 | $3.70 Million | $-8.21 Million | -2.217x | +82.36% |
| 2016-12-31 | $1.32 Million | $-16.56 Million | -12.565x | -346.74% |
| 2015-12-31 | $3.44 Million | $-9.67 Million | -2.813x | -705.22% |
| 2014-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | 0.00% |
| 2013-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | +81819.04% |
| 2012-12-31 | $-140.50K | $-79.70 | 0.001x | -- |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more